CN114601748A

CN114601748A - Soothing and repairing composition and application thereof

Info

Publication number: CN114601748A
Application number: CN202111574761.4A
Authority: CN
Inventors: 刘建宁; 鲍熹珺; 郭芳; 韩小杰; 徐旻俊; 何先喆; 张丽丽
Original assignee: Xingzhi Yumei Shanghai Biotechnology Co ltd
Current assignee: Xingzhi Yumei Shanghai Biotechnology Co ltd
Priority date: 2021-12-21
Filing date: 2021-12-21
Publication date: 2022-06-10

Abstract

The present invention provides a soothing repair composition. The invention further provides a preparation method of the soothing and repairing composition. The present invention further provides an external preparation for skin. The invention also provides the application of the soothing and repairing composition or the skin external agent. The soothing and repairing composition and the application thereof provided by the invention have the advantages that an original barrier repairing composition is obtained, the barrier repairing composition has the effects of moisturizing, resisting inflammation, relieving, removing red, relieving itching and repairing the barrier, and has good effects in products such as essence water, essence, lotion, emulsion, cream, facial mask and the like.

Description

Soothing and repairing composition and application thereof

Technical Field

The invention belongs to the technical field of cosmetics, and relates to a soothing and repairing composition and application thereof.

Background

Sensitivity is a skin condition, and sensitive muscle users may also mentally unconsciously consider their skin to be in a sensitive condition, in addition to the skin discomfort that is manifested on the upper physiological surface. The sensitive skin has wide expression characteristic span, from the mild symptoms of skin pruritus to the severe symptoms of pimple inflammation and the like belong to the scope of sensitive muscles, the number of people with mild sensitivity (pruritus, stabbing pain and redness) in sensitive muscle users is the largest, 43.0 percent, the sensitive muscles can be improved through daily maintenance and skin care, and on the other hand, the female skin with nearly three sensitive muscles has severe problems and has the sensitive expressions of redness, swelling, inflammation and the like. Age 26-30 is the most concentrated age group for sensitive muscle users, with overnight stay, stress, and cosmetic abuse being the major factors responsible for skin problems. The product which has an anti-inflammatory component, has an anti-allergy effect and is capable of relieving, deeply preserving moisture and remarkably resisting allergy is the most urgent need of consumers of sensitive muscles at present. The existing anti-allergy soothing cosmetics mainly achieve anti-inflammation soothing by the mechanism of inhibiting inflammation, meet daily care and emergency relief of consumers, are difficult to repair skin barriers from the barrier function of the skin, and fundamentally solve sensitive muscles, deeply repair and reconstruct the barriers.

Disclosure of Invention

In view of the defects of the prior art, the invention aims to provide a soothing and repairing composition and application thereof, wherein the effects of moisturizing, resisting inflammation, relieving, removing red, relieving itching, repairing barriers and the like are realized through three barriers (a physical barrier, a biological barrier and an immune barrier) in a layer-by-layer progression manner.

In order to achieve the above and other related objects, the present invention provides, in a first aspect, a soothing and repairing composition comprising collagen, a biopolysaccharide, a rhamnose soothing agent, and ceramide.

Preferably, the soothing repair composition comprises the following components in parts by weight: 0.001-1.0 parts of collagen; 0.01-0.30 parts of biological polysaccharide; 0.1-5.0 parts of rhamnose moderator; 0.01-3.0 parts of ceramide.

More preferably, the soothing repair composition comprises the following components in parts by weight: 0.01-0.5 parts of collagen; 0.05-0.25 part of biological polysaccharide; 0.5-2.0 parts of rhamnose moderator; 0.05-1.0 part of ceramide.

Preferably, the collagen is recombinant type III humanized collagen.

Preferably, the biopolysaccharide is a natural cationic biopolysaccharide.

More preferably, the biopolysaccharide is carboxymethyl chitosan.

In a second aspect, the invention provides a method for preparing a soothing and repairing composition, which comprises mixing the components of the soothing and repairing composition of the first aspect of the invention according to a certain ratio to provide the soothing and repairing composition.

In a third aspect, the present invention provides a skin external preparation comprising the soothing repair composition according to the first aspect of the present invention.

Preferably, in the skin external preparation, the collagen accounts for 0.001-1.0% of the weight of the skin external preparation; the addition amount of the biological polysaccharide accounts for 0.01-0.30% of the weight of the skin external preparation; the addition amount of the rhamnose soothing agent accounts for 0.1-5.0% of the weight of the external skin preparation; the ceramide accounts for 0.01-3.0% of the weight of the skin external preparation.

More preferably, in the skin external preparation, the collagen is added in an amount of 0.01 to 0.5 percent by weight of the skin external preparation; the addition amount of the biological polysaccharide accounts for 0.05-0.25% of the weight of the skin external preparation; the addition amount of the rhamnose soothing agent accounts for 0.5-2.0% of the weight of the external skin preparation; the ceramide accounts for 0.05-1.0% of the weight of the skin external preparation.

A fourth aspect of the invention provides the use of the soothing repair composition provided by the first aspect of the invention, or the topical skin preparation provided by the third aspect of the invention, in any one or more of:

(1) skin care;

(2) anti-inflammatory soothing of the skin;

(3) removing red skin and relieving itching;

(4) barrier repair of the skin.

Preferably, the invention also provides the use of the soothing and repairing composition provided by the first aspect of the invention or the external preparation for skin provided by the third aspect of the invention in cosmeceutical treatment of any one or more of skin care, anti-inflammatory and soothing of skin, red-dispelling and itching-relieving of skin, and barrier repair of skin.

As described above, the soothing and repairing composition and the application thereof provided by the invention obtain an original barrier repairing composition through preferred components and content ranges thereof, and realize anti-inflammatory soothing and barrier repairing through layer-by-layer progression of three barriers (physical barrier, biological barrier and immune barrier). The soothing and repairing composition is novel and original, has good water solubility, is easy to add and apply, can be widely applied to skin care and color cosmetics products, has good effects when being conveniently added into products such as essence water, essence liquid, lotion, emulsion, cream, mask and the like, and has the effects of moisturizing, resisting inflammation, relieving, dispelling red, relieving itching and repairing barriers.

Drawings

FIG. 1 is a graph showing the results of the degranulation morphology microscopy of mouse mast cell (P815) cells against Negative Control (NC) in the present invention.

FIG. 2 is a graph showing the result of the cell degranulation morphology microscopy of mouse mast cells (P815) against a model control (M) in the present invention.

FIG. 3 is a diagram showing the result of the degranulation morphology microscopy of mouse mast cell (P815) cells against Positive Control (PC) in the present invention.

FIG. 4 shows the result of the degranulation morphology microscopy of mouse mast cell (P815) cells in the sample group (TA) of the present invention in FIGS. 4a, 4b, and 4c, wherein FIG. 4a is a graph of the result of the degranulation morphology microscopy of mouse mast cell (P815) cells in 0.60% of the sample group (TA); 4b is a 0.20% sample group (TA) granulometric morphology microscopy result plot of mouse mast cell (P815) cells; 4c is a 0.06% sample group (TA) granulometric morphology microscopy of mouse mast cell (P815) cells.

Fig. 5 is a graph showing a comparison of relative areas of different scratch groups according to the present invention.

FIG. 6 shows images 6a, 6b, 6c, 6d, 6e, 6f, 6g, 6h, 6i, 6j, 6k, 6l, 6m, 6n, 6o of different groups of cell microscopes 100X of the present invention, wherein,

FIG. 6a is a cell micrograph of Negative Control (NC) at 0 h; FIG. 6b is a cell micrograph of Negative Control (NC) at 12 h; FIG. 6c is a cell micrograph of Negative Control (NC) at 24 h;

FIG. 6d is a cell micrograph of Positive Control (PC) at 0 h; FIG. 6e is a microscopic photograph of Positive Control (PC) cells at 12 h; FIG. 6f is a cell micrograph of Positive Control (PC) at 24 h;

FIG. 6g is a cell micrograph at 0h of the 1.0% sample group (TA); FIG. 6h is a cell micrograph at 12h of 1.0% of the sample group (TA); FIG. 6i is a cell micrograph at 24h of the 1.0% sample group (TA);

FIG. 6j is a cell micrograph at 0h of the 0.5% sample group (TA); FIG. 6k is a cellular micrograph at 12h of the 0.5% sample group (TA); FIG. 6l is a cell micrograph at 24h of the 0.5% sample group (TA);

FIG. 6m is a cell micrograph at 0h of the 0.25% sample group (TA); FIG. 6n is a cell micrograph at 12h of the 0.25% sample group (TA); FIG. 6o is a cell micrograph at 24h of the 0.25% sample group (TA).

Detailed Description

In a first aspect, the invention provides a soothing and repairing composition (Yohealix-4R) comprising collagen, a biological polysaccharide, a rhamnose soothing agent and ceramide.

In a preferred embodiment, the soothing repair composition comprises the following components in parts by weight: 0.001-1.0 part of collagen; 0.01-0.30 parts of biological polysaccharide; 0.1-5.0 parts of rhamnose moderator; 0.01-3.0 parts of ceramide.

In a further preferred embodiment, the soothing repair composition comprises the following components in parts by weight:

0.01-0.5 parts of collagen; specifically, 0.01 to 0.1 part, 0.1 to 0.2 part, 0.2 to 0.3 part, 0.3 to 0.4 part, 0.4 to 0.5 part;

0.05-0.25 part of biological polysaccharide; specifically, 0.05 to 0.1 part, 0.1 to 0.15 part, 0.15 to 0.20 part and 0.20 to 0.25 part;

0.5-2.0 parts of rhamnose moderator; specifically, 0.5 to 1.0 part, 1.0 to 1.5 parts and 1.5 to 2.0 parts;

0.05-1.0 part of ceramide; specifically, 0.05 to 0.1 part, 0.1 to 0.3 part, 0.3 to 0.5 part, 0.5 to 0.7 part, and 0.7 to 1.0 part.

In a preferred embodiment, the collagen is a recombinant type III humanized collagen.

In the present invention, the collagen is a structural protein constituting an extracellular matrix (ECM), provides a growth space for cells, and has a supporting function; in addition, the compound also has the functions of signal transduction, growth factor and cytokine transmission. Collagen springs in the skin and supports the skin. With age, skin collagen synthesis decreases. The stimulation of external environment (UV, etc.) can promote the decomposition of collagen, the collagen fiber can be broken, the skin can lose softness, elasticity and luster, meanwhile, the fiber of dermis is broken, lipoatrophy, sweat gland and sebaceous gland secretion is reduced, and the skin can have a series of aging phenomena such as color spots, wrinkles, impaired barrier function, and the like.

In the invention, the recombinant III-type humanized collagen is a conventionally used recombinant III-type humanized collagen, and is a full-length or partial amino acid sequence fragment encoded by a specific type gene of human collagen prepared by a DNA recombination technology, or a combination containing functional fragments of human collagen. The recombinant type III humanized collagen has a characteristic structure of collagen: G-X-Y repeating structure, wherein G represents Glycine (Glycine), X is mainly Proline (Proline), and Y is mainly hydroxyproline (Hyp). Specifically, for example, the recombinant type III humanized collagen is recombinant type III collagen powder produced by Jiangsu Chuangjian medical science and technology Limited.

In a preferred embodiment, the biopolysaccharide is a natural cationic biopolysaccharide.

In a further preferred embodiment, the biopolysaccharide is carboxymethyl chitosan (CAS number 83512-85-0).

In the invention, the carboxymethyl chitosan is derived from marine organisms and is the only natural cationic biological polysaccharide in nature. It is formed by introducing carboxymethyl into the carboxyl of O-carboxymethyl chitosan to destroy the hydrogen bond in chitosan molecule. It has good water solubility, and can be dissolved in pH neutral aqueous solution; contains polar hydrophilic groups such as hydroxyl, amino, carboxyl and the like, so that the water absorption is stronger and is enhanced along with the increase of the substitution degree of carboxymethyl; part of acetamido is reserved, which is beneficial to the spreadability and the skin feel of the mask; ensure that the amino group is not substituted by carboxymethyl, and ensure the cationic property and the biological activity of the amino group.

Due to the three major pain point symptoms of the sensitive muscles of the human body at present: sensitivity, inflammatory reaction, skin itching. The carboxymethyl chitosan can obviously reduce the levels of interleukin-6 and TNF-alpha, thereby achieving the effect of relieving skin inflammation; meanwhile, the carboxymethyl chitosan and the H1 histamine receptor are combined in a competitive way with high affinity, so that the histamine is prevented from activating the itch-causing H1 receptor, and the itch of skin caused by the histamine is rapidly relieved; promoting the growth of fibroblasts, accelerating the healing of wounds and quickly repairing the barrier function of the stratum corneum.

In a preferred embodiment, the rhamnose-moderator is a rhamnose-moderator which is conventionally used. In particular, the rhamnose soothing agent is a yuexinsoft HP 1.5P soothing agent manufactured by the company of mantine France, and the product code is 300-RHAMINO 2. The rhamnose soothing agent is a soothing agent taking bioglycan-2 as a main component.

In the invention, the rhamnose soothing agent is a polysaccharide aqueous solution obtained by bacterial fermentation, the polymer has a branch structure and can completely express a sugar sequence of a saccharide acting in cellular immunity, and the saccharide structure of the rhamnose soothing agent is rich in rhamnose, so that the rhamnose soothing agent can inhibit information transfer of skin cells after the skin cells are disturbed, thereby achieving the purpose of reducing inflammatory reaction. Rhamnose soothing agents also combine protection and pleasure by promoting the synthesis of skin pleasure factors such as endorphins.

In a preferred embodiment, the ceramide is a conventionally used ceramide (CAS number 100403-19-8). In particular, the ceramide may be a ceramide of the SK-INFLUX V MB type produced by Shanghai-Technida, Inc. and an aqueous solution preparation of phytosphingosine.

In the invention, the ceramide belongs to sphingolipid, is a compound consisting of fatty acid and sphingolipid base, and has the following effects: (1) maintaining and enhancing skin barrier function and its anti-allergy effects; the omega-OH ceramide can be covalently bonded to the incrustation protein of the cornified envelope of the keratinocyte, thereby connecting the lipid matrix and the keratinocyte, enhancing the barrier function of the skin, and reducing harmful substances from entering the skin through pores and sweat glands, thereby having anti-allergy effect. (2) Moisturizing and hydrating effects; ceramide can obviously promote the expression level of filaggrin mRNA and protein. Wherein, when entering stratum corneum from the stratum granulosum, the filaggrin is converted into polycarboxylic acid substances through a series of enzyme hydrolysis, and the moisturizing effect is achieved. Silk fibroin is not only an important structural protein, but also a major source of moisturizing factors. (3) Antioxidant and antiaging effects; the sphingosine carbon chain in the ceramide has double bonds and terminal hydroxyl, which indicates that the ceramide is easy to oxidize to break the double bonds, thereby having the effect of resisting oxidation. The low concentration of ceramide can stimulate the proliferation of fibroblasts and inhibit the expression of matrix metalloproteinase, so that the ceramide has certain anti-aging effect.

In the invention, the carboxymethyl chitosan in the soothing and repairing composition can quickly relieve itching, inhibit inflammation and repair barriers; the compound ceramide can enhance skin moisture retention and restore lipid barrier; the recombined III-type humanized collagen has the functions of moisturizing, nourishing, deeply repairing and promoting the generation of III-type collagen; the rhamnose soothing agent releases pleasure factors such as endorphins through the skin and improves the self-healing force of the skin. The above components have synergistic effect, and can be gradually applied via three barriers (physical barrier, biological barrier, and immunological barrier) to achieve effects of supplementing water, keeping moisture, relieving inflammation, relieving itching, and repairing barrier.

In a preferred embodiment, the temperature of the mixing is normal temperature. The normal temperature is 20-30 ℃.

In a preferred embodiment, the mixing is stirred dispersion. The conditions of the stirring such as the rotation speed and the time are not limited as long as the components are completely dispersed.

In a preferred embodiment, in the skin external preparation, the collagen is added in an amount of 0.001 to 1.0% by weight of the skin external preparation; the addition amount of the biological polysaccharide accounts for 0.01-0.30% of the weight of the skin external preparation; the addition amount of the rhamnose soothing agent accounts for 0.1-5.0% of the weight of the external skin preparation; the ceramide accounts for 0.01-3.0% of the weight of the skin external preparation.

In a further preferred embodiment, in the skin external preparation, the collagen is added in an amount of 0.01 to 0.5% by weight of the skin external preparation; the addition amount of the biological polysaccharide accounts for 0.05-0.25% of the weight of the skin external preparation; the addition amount of the rhamnose soothing agent accounts for 0.5-2.0% of the weight of the external skin preparation; the ceramide accounts for 0.05-1.0% of the weight of the skin external preparation.

In a preferred embodiment, the skin external agent may be formulated in various product forms including, but not limited to, basic cosmetics, facial makeup cosmetics, body makeup cosmetics, head care products, and the like. The skin external agent is a general concept of skin care and color cosmetic products generally used for the external skin.

In further preferred embodiments, the skin external agent includes, but is not limited to, essence water, lotion, essence liquid, mask, gel, emulsion, cream, and the like. The external skin preparation herein can be prepared using a conventional method for preparing such a composition.

In a further preferred embodiment, when the skin external agent is essence water, the skin external agent comprises the following components in percentage by weight: 4-6% of 1, 3-butanediol; PE 90100.3-0.5%; 0.001-1.0% of collagen; 0.01-0.30% of biological polysaccharide; 0.1-5.0% of rhamnose soothing agent; 0.01-3.0% of ceramide; the balance being water.

In the most preferred embodiment, when the external skin preparation is essence water, the external skin preparation comprises the following components in percentage by weight: 5% of 1, 3-butanediol; PE 90100.4%; 0.01-0.5% of collagen; 0.05-0.25% of biological polysaccharide; 0.5-2.0% of rhamnose soothing agent; 0.05-1.0% of ceramide; the balance being water.

In a further preferred embodiment, when the skin external agent is a cosmetic water, the skin external agent comprises the following components in percentage by weight: 4-6% of glycerol; 2-4% of dipropylene glycol; 1-3% of 1, 3-butanediol; 0.05 to 0.15 percent of dipotassium glycyrrhizinate; trehalose 0.05-0.15%; 0.3 to 0.5 percent of panthenol; 0.01 to 0.10 percent of sodium hyaluronate; 0.05 to 0.15 percent of allantoin; 1-3% of nicotinamide; 0.3 to 0.5 percent of p-hydroxyacetophenone; 0.3 to 0.5 percent of phenoxyethanol; 0.10-0.20% of PEG-60 hydrogenated castor oil; 0.01 to 0.10 percent of essence; 0.001-1.0% of collagen; 0.01-0.30% of biological polysaccharide; 0.1-5.0% of rhamnose soothing agent; 0.01-3.0% of ceramide; the balance being water.

In the most preferred embodiment, when the skin external agent is a cosmetic water, the skin external agent comprises the following components in percentage by weight: 5% of glycerol; 3% of dipropylene glycol; 2% of 1, 3-butanediol; dipotassium glycyrrhizinate 0.1%; 0.1% of trehalose; 0.4 percent of panthenol; 0.05% of sodium hyaluronate; 0.1 percent of allantoin; 2% of nicotinamide; 0.4 percent of p-hydroxyacetophenone; 0.4 percent of phenoxyethanol; 0.15% of PEG-60 hydrogenated castor oil; 0.05% of essence; 0.01-0.5% of collagen; 0.05-0.25% of biological polysaccharide; 0.5-2.0% of rhamnose soothing agent; 0.05-1.0% of ceramide; the balance being water.

In a further preferred embodiment, when the external skin preparation is a serum, the external skin preparation comprises the following components in percentage by weight: 4-6% of glycerol; 2-4% of dipropylene glycol; 1-3% of 1, 3-butanediol; 0.05 to 0.15 percent of dipotassium glycyrrhizinate; trehalose 0.05-0.15%; 0.3 to 0.5 percent of panthenol; 0.01 to 0.10 percent of sodium hyaluronate; 0.05 to 0.15 percent of allantoin; 1-3% of nicotinamide; 0.05 to 0.15 percent of xanthan gum; carbomer 0.05-0.15%; 0.01-0.10% of tromethamine; 1-3% of bis-PEG-18 methyl ether dimethylsilane; 0.3 to 0.5 percent of p-hydroxyacetophenone; 0.3 to 0.5 percent of phenoxyethanol; 0.05 to 0.15 percent of tocopherol acetate; 0.10-0.20% of PEG-60 hydrogenated castor oil; 0.01 to 0.10 percent of essence; 0.001-1.0% of collagen; 0.01-0.30% of biological polysaccharide; 0.1-5.0% of rhamnose soothing agent; 0.01-3.0% of ceramide; the balance being water.

In the most preferred embodiment, when the external skin preparation is a serum, the external skin preparation comprises the following components in percentage by weight: 5% of glycerol; 3% of dipropylene glycol; 2% of 1, 3-butanediol; dipotassium glycyrrhizinate 0.1%; 0.1% of trehalose; 0.4 percent of panthenol; 0.05% of sodium hyaluronate; 0.1 percent of allantoin; 2% of nicotinamide; 0.1% of xanthan gum; 0.1% of carbomer; 0.06 percent of tromethamine; 2% of bis-PEG-18 methyl ether dimethylsilane; 0.4 percent of p-hydroxyacetophenone; 0.4 percent of phenoxyethanol; 0.1% of tocopherol acetate; 0.15% of PEG-60 hydrogenated castor oil; 0.05% of essence; 0.01-0.5% of collagen; 0.05-0.25% of biological polysaccharide; 0.5-2.0% of rhamnose soothing agent; 0.05-1.0% of ceramide; the balance being water.

In a further preferred embodiment, when the skin external agent is an emulsion, the skin external agent comprises the following components in percentage by weight: 4-6% of glycerol; 2-4% of dipropylene glycol; 1-3% of 1, 3-butanediol; 0.05 to 0.15 percent of dipotassium glycyrrhizinate; trehalose 0.05-0.15%; 0.5 to 1.5 percent of panthenol; 0.01 to 0.10 percent of sodium hyaluronate; 0.05 to 0.15 percent of allantoin; 1-3% of nicotinamide; 0.05 to 0.15 percent of xanthan gum; caprylic/capric triglyceride 2-4%; 3-5% of dioctyl carbonate; 1-3% of squalane; 0.5-1.5% of jojoba seed oil; cetostearyl alcohol 0.5-1.5%; arlacel 1651-3%; 1-3% of polydimethylsiloxane; acrylic acid (ester)/C10-30 alkanol acrylate crosslinked polymer 0.10-0.20%; 0.05 to 0.15 percent of tromethamine; 0.3 to 0.5 percent of p-hydroxyacetophenone; 0.3 to 0.5 percent of phenoxyethanol; 0.05 to 0.15 percent of tocopherol acetate; 0.01 to 0.10 percent of essence; 0.001-1.0% of collagen; 0.01-0.30% of biological polysaccharide; 0.1-5.0% of rhamnose soothing agent; 0.01-3.0% of ceramide; the balance being water.

In the most preferred embodiment, when the skin external agent is an emulsion, the skin external agent comprises the following components in percentage by weight: 5% of glycerol; 3% of dipropylene glycol; 2% of 1, 3-butanediol; dipotassium glycyrrhizinate 0.1%; 0.1% of trehalose; 1.0% of panthenol; 0.05% of sodium hyaluronate; 0.1 percent of allantoin; 2% of nicotinamide; 0.1% of xanthan gum; caprylic/capric triglyceride 3%; 4% of dioctyl carbonate; 2% of squalane; jojoba seed oil 1.0%; cetostearyl alcohol 1.0%; arlacel 1652.0%; 2.0% of polydimethylsiloxane; acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer 0.15%; 0.1 percent of tromethamine; 0.4 percent of p-hydroxyacetophenone; 0.4 percent of phenoxyethanol; 0.1% of tocopherol acetate; 0.05% of essence; 0.01-0.5% of collagen; 0.05-0.25% of biological polysaccharide; 0.5-2.0% of rhamnose soothing agent; 0.05-1.0% of ceramide; the balance being water.

In a further preferred embodiment, when the external skin preparation is a cream, the external skin preparation comprises the following components in percentage by weight: 4-6% of glycerol; 2-4% of dipropylene glycol; 1-3% of 1, 3-butanediol; dipotassium glycyrrhizinate 0.05-0.15%; trehalose 0.05-0.15%; 0.5 to 1.5 percent of panthenol; 0.01 to 0.10 percent of sodium hyaluronate; 0.05 to 0.15 percent of allantoin; 1-3% of nicotinamide; 0.05 to 0.15 percent of xanthan gum; caprylic/capric triglyceride 2-4%; 3-5% of cetearyl ethyl hexanoate; 2-4% of squalane; 0.5-1.5% of jojoba seed oil; 1-3% of cetearyl alcohol; 1-3% of shea butter; arlacel 1651-3%; 2-4% of polydimethylsiloxane; acrylic acid (ester)/C10-30 alkanol acrylate crosslinked polymer 0.1-0.3%; 0.05 to 0.15 percent of tromethamine; 0.3 to 0.5 percent of p-hydroxyacetophenone; 0.3 to 0.5 percent of phenoxyethanol; 0.05 to 0.15 percent of tocopherol acetate; 0.01 to 0.10 percent of essence; 0.01-0.5% of collagen; 0.05-0.25% of biological polysaccharide; 0.5-2.0% of rhamnose soothing agent; 0.05-1.0% of ceramide; the balance being water.

In the most preferred embodiment, when the external skin preparation is a cream, the external skin preparation comprises the following components in percentage by weight: 5% of glycerol; 3% of dipropylene glycol; 2% of 1, 3-butanediol; dipotassium glycyrrhizinate 0.1%; 0.1% of trehalose; 1.0% of panthenol; 0.05% of sodium hyaluronate; 0.1 percent of allantoin; 2% of nicotinamide; 0.1% of xanthan gum; caprylic/capric triglyceride 3%; cetearyl ethyl hexanoate 4%; 3% of squalane; jojoba seed oil 1.0%; cetostearyl alcohol 2.0%; 2.0% of shea butter; arlacel 1652.0%; 3.0% of polydimethylsiloxane; acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer 0.2%; 0.1 percent of tromethamine; 0.4 percent of p-hydroxyacetophenone; 0.4 percent of phenoxyethanol; 0.1% of tocopherol acetate; 0.05% of essence; 0.01-0.5% of collagen; 0.05-0.25% of biological polysaccharide; 0.5-2.0% of rhamnose soothing agent; 0.05-1.0% of ceramide; the balance being water.

The skin external preparation comprises the following components:

the PE 9010 is a liquid preservative for cosmetics compounded by phenoxyethanol and ethylhexylglycerin. Specifically, the PE 9010 is a liquid preservative for cosmetics, which is prepared by compounding phenoxyethanol and ethylhexyl glycerin and is produced by Germany Shumei company.

The above-mentioned 1, 3-butanediol (CAS number 107-88-0); glycerol (CAS number 56-81-5); dipropylene glycol (CAS number 25265-71-8); dipotassium glycyrrhizinate (CAS number 68797-35-3); trehalose (CAS number 99-20-7); panthenol (CAS number 81-13-0); sodium hyaluronate (CAS number 9067-32-7); allantoin (CAS number 97-59-6); nicotinamide (CAS number 98-92-0); p-hydroxyacetophenone (CAS number 99-93-4); phenoxyethanol (CAS number 122-99-6); PEG-60 hydrogenated Castor oil (CAS number 61788-85-0); xanthan gum (CAS number 11138-66-2); carbomer (CAS No. 9007-20-9); tromethamine (CAS number 77-86-1); bis-PEG-18 methyl ether dimethylsilane (CAS number 67846-47-3); tocopheryl acetate (CAS number 7695-91-2); caprylic/capric triglyceride (CAS number 73398-61-5); dioctyl carbonate (CAS number 1680-31-5); squalane (CAS number 111-01-3); jojoba seed oil (CAS number 61789-91-1); cetostearyl alcohol (CAS number 246159-33-1); self-emulsifying glyceryl monostearate (Arlacel 165) (CAS number 84750-06-1); polydimethylsiloxane (CAS number 9006-65-9); cetearyl ethylhexanoate (CAS number 90411-68-0); shea butter (CAS number 194043-92-0).

The acrylic acid (ester)/C10-30 alkanol acrylate crosslinked polymer is a conventionally used acrylic acid (ester)/C10-30 alkanol acrylate crosslinked polymer. In particular Pemulen produced by Luborun, USA^TMTR-1 polymer.

The essence is conventionally used. In particular to a Fragrance86396582 type essence produced by the Swiss Qiwashington company.

The water is deionized water.

In a preferred embodiment, the formulation of the external preparation for skin is not particularly limited and may be appropriately selected depending on the purpose. The formulation of the external preparation for skin includes, but is not limited to, aqueous phase, oil phase, gel, oil-in-water emulsion, water-in-oil emulsion, etc.

In a preferred embodiment, the skin external preparation further comprises one or more conventional other active ingredients.

In the present invention, the content of the other active ingredients is a content conventional in the art. The other active ingredients have one or more effects of moisturizing, whitening, resisting oxidation, controlling oil, removing acne, resisting wrinkle and tightening skin external preparation.

The external preparation for skin may further contain a vehicle or a base excipient conventionally used in the art according to various formulations and purposes, as long as the excipient is an acceptable excipient in the cosmetic field, according to the general knowledge in the art. The excipient content is the content conventional in the art.

In the present invention, the excipient may be in the form of a water phase, an oil phase, a gel, an oil-in-water emulsion, or a water-in-oil emulsion. The aqueous phase may be a mixture of one or more water soluble or dispersible components, which may be liquid, semi-solid or solid at room temperature. The form of suitable excipients, and the components contained therein, may be selected by those skilled in the art based on the knowledge of those skilled in the art.

(1) skin care;

(2) anti-inflammatory soothing of the skin;

(3) removing red skin and relieving itching;

(4) barrier repair of the skin.

In the present invention, the invention also provides the use of the soothing and repairing composition provided in the first aspect of the invention or the external preparation for skin provided in the third aspect of the invention in cosmeceutical for treating any one or more of skin care, anti-inflammatory and soothing of skin, red-dispelling and itching-relieving of skin, and barrier repair of skin.

In the present invention, "skin care" means regulating and/or improving the condition of the skin. In some non-limiting examples, improving skin appearance and/or feel by providing a smoother, more uniform appearance and/or feel, reducing lesion thickness, improving skin elasticity or resiliency, improving skin firmness, reducing the appearance of skin dullness, improving the hydration or moisturization state of the skin, improving the appearance of fine lines and/or wrinkles, improving skin tone, reducing the appearance of redness or skin rash, improving the brightness, radiance, and the like of the skin.

The soothing repair compositions and topical skin preparations herein are intended for topical application to the skin. The compositions of the present invention are useful for treating a variety of skin conditions, such as, for example, those associated with or caused by inflammation; stretch marks; redness of the skin; damage by sunlight; sallow or yellowish skin; dull skin; aging (intrinsic or extrinsic); hyperpigmentation; UV exposure; rough texture, wrinkles, damaged skin barrier (e.g., dry skin); dermatitis; eczema, etc.

When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition to the specific methods, devices, and materials used in the examples, any methods, devices, and materials similar or equivalent to those described in the examples may be used in the practice of the invention in addition to the specific methods, devices, and materials used in the examples, in keeping with the knowledge of one skilled in the art and with the description of the invention.

Unless otherwise indicated, the experimental methods, detection methods, and preparation methods disclosed herein all employ techniques conventional in the art of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related arts.

The term "individual" or "patient" as used herein refers to humans, wild animals and domestic animals suffering from a disease, preferably a mammal, especially a human being is selected.

The present invention is further illustrated below with reference to specific examples, which are intended to be illustrative only and not to limit the scope of the invention.

The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.

Examples 1 to 4

The components of the soothing and repairing composition were mixed in parts by weight according to the composition of table 1 below to prepare sample # 1-4 of the soothing and repairing composition.

TABLE 1

Numbering	Name of composition	Example 1	Example 2	Example 3	Example 4
						1	Recombinant type III humanized collagen (parts by weight)	0.01	0.05	0.1	0.5
2	Carboxymethyl chitosan (parts by weight)	0.05	0.1	0.25	0.25
						3	Rhamnose soothing agent (parts by weight)	0.5	0.5	1	2
4	Ceramide (parts by weight)	0.05	0.1	0.5	1

Examples 5 to 8

Taking the # 1-4 of the soothing repairing composition samples in examples 1-4, adding other active ingredients of the conventional soothing repairing composition aqueous solution, dissolving, stirring and dispersing completely at room temperature to prepare # 1-4 of the soothing repairing composition aqueous solution samples, wherein the content and composition of each ingredient in the # 1-4 of the soothing repairing composition aqueous solution samples are shown in the following table 2.

TABLE 2

Examples 9 to 12

Taking samples 1-4# of the soothing and repairing composition in examples 1-4, adding other active ingredients of the conventional astringent, preparing the astringent samples 1-4# according to the preparation method of the astringent conventional in the field, wherein the content composition of each ingredient in the astringent samples 1-4# is shown in the following table 3.

TABLE 3

Numbering	Name of composition	Example 9	Example 10	Example 11	Example 12
						1	Deionized water	To 100	To 100	To 100	To 100
2	Glycerol	5	5	5	5
						3	Dipropylene glycol	3	5	5	5
4	1, 3-butanediol	2	2	2	2
						5	Glycyrrhizic acid dipotassium salt	0.1	0.1	0.1	0.1
6	Trehalose	0.1	0.1	0.1	0.1
						7	Panthenol	0.4	0.4	0.4	0.4
8	Hyaluronic acid sodium salt	0.05	0.05	0.05	0.05
						9	Allantoin	0.1	0.1	0.1	0.1
10	Nicotinamide	2	2	2	2
						11	P-hydroxyacetophenone	0.4	0.4	0.4	0.4
12	Phenoxyethanol	0.4	0.4	0.4	0.4
						13	PEG-60 hydrogenated Castor oil	0.15	0.15	0.15	0.15
14	Essence	0.05	0.05	0.05	0.05
						15	Recombinant type III humanized collagen	0.01	0.05	0.1	0.5
16	Carboxymethyl chitosan	0.05	0.1	0.25	0.25
						17	Rhamnose soothing agent	0.5	0.5	1	2
18	Ceramide	0.05	0.1	0.5	1

Examples 13 to 16

Taking the # 1-4 soothing and repairing composition samples of examples 1-4, adding other active ingredients of the conventional essence, and preparing the # 1-4 essence according to the conventional preparation method of the essence in the field, wherein the content composition of each ingredient in the # 1-4 essence is shown in the following table 4.

TABLE 4

Examples 17 to 20

Taking samples 1-4# of the soothing repair composition of examples 1-4, mixing with other active ingredients of a conventional emulsion, and preparing to obtain emulsion samples 1-4# according to a preparation method of the emulsion conventional in the art, wherein the content composition of each ingredient in the emulsion samples 1-4# is shown in the following table 5.

TABLE 5

Examples 21 to 24

Samples 1-4# of the soothing and repairing composition of examples 1-4 were taken, and other active ingredients of the conventional cream were added, and cream samples 1-4# were prepared according to the conventional cream preparation method in the art, and the content composition of each ingredient in the cream samples 1-4# is shown in table 6 below.

TABLE 6

Example 25

Inflammation is one of the most common conditions in the clinic and is a defense response of the human body to ensure removal of noxious stimuli and repair of damaged tissues. When immune cells of human body are acted by inflammatory factors, some soluble proteins or polypeptides with small molecular weight, information transmission among cells and specific immunoregulation function are secreted by the body and can participate or cause inflammatory reaction, and the substances are called inflammatory factors and comprise NO, TNF-alpha, IL-6, PGE-2, IL-1 and the like. They are all important cell active factors in inflammatory reaction, have direct or indirect effect on cell inflammation, and have influence on each other.

IL-6 is a multifunctional cytokine, has the functions of anti-inflammation and inflammation-causing, the function of the IL-6 is related to the content of tissues, and the normal level of IL-6 is beneficial to the body and can cause a series of inflammatory injuries when being excessively generated; PGE-2 is the major prostaglandin product of the COX-2 enzyme activity pathway and is the major inflammatory mediator of diseases such as rheumatoid arthritis and osteoarthritis.

Thus, the effect of the example soothing repair compositions prepared in the present invention on the inflammatory factors IL-6 and PGE-2 was verified. A

1. Experimental materials:

cell line: raw246.7 cells (P7)

Culture medium: DMEM medium containing 10% FBS (FBS from GIBCO, Lot:42Q1095K)

And (3) testing conditions are as follows: 37 ℃ and 5% CO₂Cultivation under saturated humidity conditions

Solution and control:

MTT solution: 5mg/mL

LPS: diluted to 1mg/mL with ultrapure water and stored at-20 deg.C (purchased from Sigma).

Blank control (NT): DMEM medium without serum.

Model group (M): serum free DMEM medium was supplemented with LPS to a final concentration of 1. mu.g/mL.

Test substance (TA): the sample 3# of the soothing repair composition of example 3 was diluted to the desired test concentration with serum-free DMEM medium and LPS was added to a final concentration of 1. mu.g/mL as a sample.

Positive Control (PC): serum free DMEM medium, dexamethasone and LPS were added to final concentrations of 0.5. mu.g/mL and 1. mu.g/mL, respectively.

The kit comprises: PGE2 ELISA Kit (Batch: 0618063) was purchased from Cayman, USA;

an ELISA kit for IL-6 (Lot: M210719-004a) was purchased from Shenzhen Xinbo Sheng Biotech, Inc.

2. The test steps are as follows:

cell activity assay:

2.1 cells were routinely cultured. The preparation density is 0.8-1.0 x 10⁵one/mL of cell suspension, the cell suspension was seeded into 96-well cell culture plates at 100. mu.L per well and cultured for 18-24 h.

2.2 discarding the original culture solution in the holes, adding 100 mu L of samples to be tested with different concentrations into each hole, and returning to the incubator for incubation for 24 +/-1 h.

2.3 the plates were removed and 20. mu.L of MTT solution was added to each well and the incubator incubated for 3-4 h. Removing liquid in the wells, adding 100 μ L DMSO into each well, placing in an oscillator, oscillating for 10-15min, and measuring absorbance at 570nm wavelength of a microplate reader.

2.4 data analysis: cell activity relative cell activity (viatility) was calculated for each group, taking the cell activity of the blank group as 100%.

Cellular anti-inflammatory assay:

2.5 culturing the cells in a conventional manner at a density of 2.0 to 3.0X 10⁵Inoculating one/well into 12-well plate, and returning to the incubator for 18-24 h.

2.6 removing the culture plate, discarding the original culture solution in the wells, adding 1mL of culture solution containing different concentrations of the test sample and LPS (1. mu.g/mL) to each well of the sample group, adding culture solution containing LPS (1. mu.g/mL) as a stimulus to the model group, adding 1mL of culture solution containing dexamethasone (0.5. mu.g/mL) and LPS (1. mu.g/mL) to the positive control group, adding culture solution to the control group, and culturing for 24 + -1 h.

2.7 the supernatant was collected, stored at-80 ℃ and the cytokines were measured using an ELISA kit.

2.8 data analysis: data are presented as mean ± standard deviation, and data are analyzed using SPSS, considering that differences are statistically significant if p < 0.05.

3. And (3) test results:

3.1 results of cell activity assays are shown in Table 7 below.

TABLE 7 relative Activity of the groups of cells (Mean. + -. SD)

As can be seen from table 7, 6.00%, 2.00%, 0.60% were screened as the test concentrations for the subsequent efficacy experiments.

3.2 anti-inflammatory assay of cells, the results of the PGE2 assay are shown in Table 8 below, and the results of the IL-6 assay are shown in Table 9 below.

TABLE 8 comparison of the differences in PGE2 of different groups

#: p <0.05, the difference was statistically significant compared to the blank control (NT).

*: p <0.05, the difference was statistically significant compared to model group (M).

TABLE 9 comparison of IL-6 differences between different groups

*: p <0.05, the difference was statistically significant compared to the model group (M)

4. And (4) test conclusion:

under the test condition of 3.1, compared with a blank control group, the content of PGE2 in the model group is obviously increased by 27.92 percent (P is less than 0.05), and compared with the model group, the content of PGE2 in the positive control group is obviously reduced by 80.22 percent (P is less than 0.05), which indicates that the molding is successful; compared with a model group, the content of PGE2 in the soothing and repairing composition Yoohealix-4R at the concentration of 2.00 percent and 0.60 percent is respectively and obviously reduced by 81.29 percent and 63.60 percent (P is less than 0.05).

Under the test condition of 3.2, compared with a blank control group, the IL-6 content of the model group is obviously increased by 18.19 percent (P <0.05), and compared with the model group, the IL-6 content of the positive control group is obviously reduced by 14.55 percent (P <0.05), which indicates that the molding is successful; compared with a model group, the content of IL-6 of the relieving and repairing composition Yoohealix-4R at the concentration of 6.00%, 2.00% and 0.60% is obviously reduced by 67.57%, 59.96% and 48.44% (P < 0.05).

The soothing healing composition yoheilix-4R showed anti-inflammatory activity in this test by sample # 3 of the soothing healing composition in the sample set of test substances (TA). Therefore, the composition has better anti-inflammatory and relieving effects on the skin.

Example 26

Mast cells are fully secreted with granules in cytoplasm, contain heparin, histamine, eotaxin and the like, and when the mast cells are stimulated by antigen, specific IgE is produced, receptors on the mast cells are activated, and specific antibodies are combined to degranulate the mast cells. The release of histamine contained in cytoplasm leads to increase of tissue wall permeability, tissue edema, skin itch and the like, and causes allergic reaction.

Thus, the effect of the example bradykinin compositions prepared in the present invention on degranulation activity of mouse mast cell (P815) cells was demonstrated.

1. Experimental Material

Cell: p815(P4)

Culture medium: DMEM medium containing 10% FBS, stored at 2-8 deg.C for 2 weeks

And (3) testing conditions are as follows: temperature 37 + -0.5 deg.C, humidity>90％，5％CO₂Concentration of

Solution and control: c48/80: purchased from Sigma, diluted to 1mg/mL with ultrapure water, filtered through a 0.22 μm filter and stored at-20 ℃.

Test sample (TA): the sample 2# of the soothing repair composition of example 2 was diluted to 100mg/mL with DMEM medium containing 10% FBS and further diluted to the desired test concentration as a sample.

Ketotifen fumarate: diluted to 100mM in DMSO, filtered through a 0.22 μm filter and stored at-20 ℃.

Neutral red: diluted to 25. mu.g/mL with 10% FBS-containing DMEM medium, filtered through a 0.22 μm filter.

The test experiment was grouped as shown in table 10 below.

Watch 10

2. Test procedure

And (3) screening cytotoxicity:

2.1 the cultured cells were seeded in 96-well plates at 0.8-1.0X 10⁴Each 100 mu L/well, then, placing in an incubator to culture for 18-24 h.

2.2 remove the original culture medium, and expose each well to 100. mu.L of different concentrations of sample dilutions for 24. + -. 0.5 h.

2.3 mu.L of MTT solution was added to each well and incubated at 37 ℃ for 3 h. + -. 0.5 h. Then, the MTT solution was removed, 100. mu.L of DMSO was added to each well, and the absorbance was measured at a wavelength of 570nm after shaking in the dark for 10 to 15 min.

2.4 data analysis: the data for each group are expressed as mean ± standard deviation, and the relative cell activity (viatility%) of each group is calculated based on the cell activity of the control group as 100%.

Mouse mast cell (P815) histamine release assay:

2.5 collecting P815 cells in log phase at 2.0-3.0 × 10⁵Inoculating the strain/mL/hole to a 24-hole plate, and culturing in an incubator for 18-24 h;

2.6 discarding the original culture solution, washing the cells twice by HBSS, adding the culture solution of neutral red with the final concentration of 25 mug/mL, returning to the incubator for incubation for 3h, and pre-loading the neutral red;

2.7, discarding the original culture solution, washing the cells twice by HBSS, adding samples with different concentrations (the samples to be detected are respectively added with 3 samples with different concentrations, a positive control group is added with 100 mu M ketotifen fumarate, and a negative control group and a model group are added with the same amount of complete culture medium) into each group for 3 multiple wells, and incubating for 1 h;

2.8HBSS cells were washed twice, then culture medium containing 10. mu.g/mL C48/80 was added to stimulate P815 to release histamine, and the reaction was stopped after incubation for 20min in ice bath for 30 min.

2.9 discard original medium, cover the cell surface with a small amount of HBSS, and take pictures under microscopic examination.

3. Test results

3.1 results of cytotoxicity experiments are shown in Table 11.

TABLE 11

As can be seen from Table 11, concentrations of 0.60%, 0.20%, and 0.06% were selected as test concentrations in subsequent experiments.

3.2 the results of the degranulation morphological microscopic examination of P815 cells are shown in FIGS. 1-4. Among them, fig. 1 is a Negative Control (NC) mouse mast cell (P815); FIG. 2 is mouse mast cells (P815) of model control (M); FIG. 3 is mouse mast cells (P815) of Positive Control (PC); fig. 4 is a sample group (TA) of mouse mast cells (P815), wherein fig. 4a is 0.60% of the sample group (TA) of mouse mast cells (P815); 4b mouse mast cells in 0.20% sample group (TA) (P815); 4c is 0.06% of mouse mast cells (P815) of the sample group (TA).

4. Conclusion of the test

Under the condition of the experiment, the obvious degranulation phenomenon exists around the P815 cells of the visible model control group (M) through microscopic examination, and the visible neutral red staining of the microscopic examination results of the negative control group (M) and the positive control group (PC) is clearer in outline and has no obvious degranulation phenomenon, thus prompting the success of molding; the soothing and repairing composition sample 2# of the sample group (TA) showed a certain degranulation of P815 cells at 0.60%, 0.20% and 0.06% concentration, but the phenomenon occurred less than that of the model control group (M), and the neutral red staining profile was more distinct.

The soothing and repairing composition yoheilix-4R was shown to inhibit P815 cell degranulation activity in this test by sample # 2 of the soothing and repairing composition in the sample set of test samples (TA). Therefore, the composition has better effects of resisting allergy, removing red, relieving itching and the like on the skin.

Example 27

The soothing and repairing composition Yoohealix-4R has the repairing effect on human keratinocytes.

1. Experimental Material

Cell line: human keratinocyte (HaCaT)

Complete medium: DMEM medium containing 10% Fetal Bovine Serum (FBS) (FBS from Gibco, Lot:42Q1095K)

Maintenance medium: DMEM medium with 1% FBS (FBS from Gibco, Lot:42Q1095K)

And (3) testing conditions are as follows: temperature 37 +/-0.5 deg.C, humidity>90％，5％CO₂Concentration of

Solution and control:

negative control group (NC): the medium is maintained.

Positive control group (PC): maintenance medium containing 1ng/mL EGF.

Test substance (TA): the sample of the soothing repairing composition sample 4# in example 4 was used as a stock solution, and was sequentially diluted to a concentration to be measured using a maintenance medium.

2. The test steps are as follows:

2.1 cell Activity assay

2.1.1 cells were routinely cultured. The preparation density is 0.8-1.0 x 10⁵one/mL of cell suspension, the cell suspension was seeded into 96-well cell culture plates at 100. mu.L per well and cultured for 18-24 h.

2.1.2 discard the original culture solution in the wells, add 100. mu.L of test sample with different concentrations in each well, return to the incubator and incubate for 48 + -1 h.

2.1.3 the plates were removed and 20. mu.L of MTT solution was added to each well and the incubator incubated for 3-4 h. Removing liquid in the wells, adding 100 μ L DMSO into each well, placing in an oscillator, oscillating for 10-15min, and measuring absorbance at 570nm wavelength of a microplate reader.

2.1.4 data analysis: cell activity relative cell activity (viatility) was calculated for each group, taking the cell activity of the negative control group as 100%.

2.2 cell scratch test

2.2.1 culturing cells conventionally, adjusting the cell density to 3.0-5.0 × 10⁵one/mL, using 24-well cell culture plates with 2-well inserts, 70. mu.L of each well was inoculated and returned to the incubator for 18-24h to cell confluence.

2.2.2 carefully remove the culture insert from the plate with forceps, a flat cell-free area is formed between the 2 wells of the culture insert. The cell layer was washed 3 times with PBS to remove exfoliated cells.

2.2.3 Add 1mL of culture containing different concentrations of test sample per well while taking images under the mirror, noted 0h, and mark the location of the acquisition.

2.2.4 every 12h, at the same marked position, pictures are taken, and are marked as 12h and 24 h.

2.2.5 data analysis: and analyzing the area of the scratch region of each image by using IPP image analysis software, and calculating the relative area by taking 0h as 100%.

3. And (3) test results:

3.1 results of cell activity assays are shown in Table 12.

TABLE 12 relative cell Activity (Mean SD) for each group

As can be seen from table 12, 1.00%, 0.50%, 0.25% were screened as test concentrations for subsequent efficacy experiments.

3.2 cell scratch test results are shown in Table 13, Table 14, FIG. 5, FIG. 6.

TABLE 13 relative scratch area size (%)

*: the difference was statistically significant compared to the control group.

TABLE 14

Group of	0h	12h		24h
					NC	FIG. 6a 100.00. + -. 2.85	FIG. 6b86.60 + -1.47	FIG. 6c 59.10. + -. 6.11
PC	FIG. 6d 100.00. + -. 6.66	FIG. 6e 62.47. + -. 4.91	FIG. 6f 4.55. + -. 4.38
				TA(1.0％)	FIG. 6g 100.00. + -. 0.51	FIG. 6h 75.74. + -. 7.60	FIG. 6i 40.45. + -. 7.75
TA(0.5％)	FIG. 6j 100.00. + -. 0.55	FIG. 6k 78.24. + -. 0.78	FIG. 6l 54.01. + -. 4.88
				TA(0.25％)	FIG. 6m 100.00. + -. 5.63	FIG. 6n78.51 + -1.70	FIG. 6o 50.80. + -. 6.75

Under the test condition of 3.2, as can be seen from table 13, table 14, fig. 5 and fig. 6, the relative scratch area of the positive control group was significantly reduced (P <0.05) compared to the negative control group at 12h, and the relative scratch area of the soothing repair composition sample No. 4 of the sample group (TA) was significantly reduced (P <0.05) at the concentrations of 1.00%, 0.50% and 0.25%. At 24h, the relative scratch area was significantly reduced in the positive control group (P <0.05) and the soothing repair composition sample # 4 of the sample group (TA) at 1.00% concentration (P <0.05) compared to the negative control group.

Through the sample No. 4 of the relieving and repairing composition in the sample group of the sample (TA) to be detected, the relieving and repairing composition Yoohealix-4R is prompted to have certain effect of promoting and repairing human keratinocytes under the concentration of 1.00%, 0.50% and 0.25%. Thus, the composition has a good barrier repair effect on the skin.

From the above examples 25-27, it can be seen that the soothing and repairing composition yoheilix-4R prepared by the invention has a good inhibiting effect on inflammatory factors IL-6 and PGE-2, inhibits degranulation activity of P815 cells, has a certain repairing promoting effect on human keratinocytes, and has good soothing and repairing, inflammation inhibiting, anti-allergic, redness removing, itching relieving, and barrier repairing effects.

While the invention has been described with respect to a preferred embodiment, it will be understood by those skilled in the art that the foregoing and other changes, omissions and deviations in the form and detail thereof may be made without departing from the scope of this invention. Those skilled in the art can make various changes, modifications and equivalent arrangements, which are equivalent to the embodiments of the present invention, without departing from the spirit and scope of the present invention, and which may be made by utilizing the techniques disclosed above; meanwhile, any changes, modifications and variations of the above-described embodiments, which are equivalent to those of the technical spirit of the present invention, are within the scope of the technical solution of the present invention.

Claims

1. A soothing and repairing composition comprises collagen, biological polysaccharide, rhamnose soothing agent and ceramide.

2. A soothing repair composition according to claim 1, comprising the following components in parts by weight:

0.001-1.0 parts of collagen;

0.01-0.30 parts of biological polysaccharide;

0.1-5.0 parts of rhamnose moderator;

0.01-3.0 parts of ceramide.

3. A palliative repair composition as claimed in any one of claims 1 or 2, wherein the collagen is recombinant type III humanized collagen; the biological polysaccharide is natural cationic biological polysaccharide.

4. A method of preparing a soothing restorative composition, comprising mixing the components of the soothing restorative composition of any of claims 1-3 in proportions to provide the soothing restorative composition.

5. An external preparation for skin comprising the soothing repair composition of any one of claims 1 to 3.

6. The external preparation for skin as claimed in claim 5, wherein the collagen is added in an amount of 0.001 to 1.0% by weight of the external preparation for skin; the addition amount of the biological polysaccharide accounts for 0.01-0.30% of the weight of the skin external preparation; the addition amount of the rhamnose soothing agent accounts for 0.1-5.0% of the weight of the external skin preparation; the ceramide accounts for 0.01-3.0% of the weight of the skin external preparation.

7. The external preparation for skin as claimed in claim 5, wherein the external preparation for skin is one selected from the group consisting of a basic cosmetic, a face makeup cosmetic, a body makeup cosmetic and a head care product.

8. The external preparation for skin as claimed in claim 7, wherein the external preparation for skin is one selected from essence water, cosmetic water, essence liquid, mask, gel, lotion, and cream.

9. The external skin preparation according to claim 8, wherein the external skin preparation comprises any one or more of the following formulations:

A) when the skin external agent is essence water, the skin external agent comprises the following components in percentage by weight: 4-6% of 1, 3-butanediol; PE 90100.3-0.5%; 0.001-1.0% of collagen; 0.01-0.30% of biological polysaccharide; 0.1-5.0% of rhamnose soothing agent; 0.01-3.0% of ceramide; the balance of water;

B) when the skin external agent is the toning lotion, the skin external agent comprises the following components in percentage by weight: 4-6% of glycerol; 2-4% of dipropylene glycol; 1-3% of 1, 3-butanediol; 0.05 to 0.15 percent of dipotassium glycyrrhizinate; trehalose 0.05-0.15%; 0.3 to 0.5 percent of panthenol; 0.01 to 0.10 percent of sodium hyaluronate; 0.05 to 0.15 percent of allantoin; 1-3% of nicotinamide; 0.3 to 0.5 percent of p-hydroxyacetophenone; 0.3 to 0.5 percent of phenoxyethanol; 0.10 to 0.20 percent of PEG-60 hydrogenated castor oil; 0.01 to 0.10 percent of essence; 0.001-1.0% of collagen; 0.01-0.30% of biological polysaccharide; 0.1-5.0% of rhamnose soothing agent; 0.01-3.0% of ceramide; the balance of water;

C) when the skin external agent is essence, the skin external agent comprises the following components in percentage by weight: 4-6% of glycerol; 2-4% of dipropylene glycol; 1-3% of 1, 3-butanediol; 0.05 to 0.15 percent of dipotassium glycyrrhizinate; trehalose 0.05-0.15%; 0.3 to 0.5 percent of panthenol; 0.01 to 0.10 percent of sodium hyaluronate; 0.05 to 0.15 percent of allantoin; 1-3% of nicotinamide; 0.05 to 0.15 percent of xanthan gum; carbomer 0.05-0.15%; 0.01-0.10% of tromethamine; 1-3% of bis-PEG-18 methyl ether dimethylsilane; 0.3 to 0.5 percent of p-hydroxyacetophenone; 0.3 to 0.5 percent of phenoxyethanol; 0.05 to 0.15 percent of tocopherol acetate; 0.10-0.20% of PEG-60 hydrogenated castor oil; 0.01 to 0.10 percent of essence; 0.001-1.0% of collagen; 0.01-0.30% of biological polysaccharide; 0.1-5.0% of rhamnose soothing agent; 0.01-3.0% of ceramide; the balance of water;

D) when the skin external agent is emulsion, the skin external agent comprises the following components in percentage by weight: 4-6% of glycerol; 2-4% of dipropylene glycol; 1-3% of 1, 3-butanediol; 0.05 to 0.15 percent of dipotassium glycyrrhizinate; trehalose 0.05-0.15%; 0.5 to 1.5 percent of panthenol; 0.01 to 0.10 percent of sodium hyaluronate; 0.05 to 0.15 percent of allantoin; 1-3% of nicotinamide; 0.05 to 0.15 percent of xanthan gum; caprylic/capric triglyceride 2-4%; 3-5% of dioctyl carbonate; 1-3% of squalane; 0.5-1.5% of jojoba seed oil; cetostearyl alcohol 0.5-1.5%; arlacel 1651-3%; 1-3% of polydimethylsiloxane; acrylic acid (ester)/C10-30 alkanol acrylate crosslinked polymer 0.10-0.20%; 0.05 to 0.15 percent of tromethamine; 0.3 to 0.5 percent of p-hydroxyacetophenone; 0.3 to 0.5 percent of phenoxyethanol; 0.05 to 0.15 percent of tocopherol acetate; 0.01 to 0.10 percent of essence; 0.001-1.0% of collagen; 0.01-0.30% of biological polysaccharide; 0.1-5.0% of rhamnose soothing agent; 0.01-3.0% of ceramide; the balance of water;

E) when the skin external agent is cream, the skin external agent comprises the following components in percentage by weight: 4-6% of glycerol; 2-4% of dipropylene glycol; 1-3% of 1, 3-butanediol; 0.05 to 0.15 percent of dipotassium glycyrrhizinate; trehalose 0.05-0.15%; 0.5 to 1.5 percent of panthenol; 0.01 to 0.10 percent of sodium hyaluronate; 0.05 to 0.15 percent of allantoin; 1-3% of nicotinamide; 0.05 to 0.15 percent of xanthan gum; caprylic/capric triglyceride 2-4%; 3-5% of cetearyl ethyl hexanoate; 2-4% of squalane; 0.5-1.5% of jojoba seed oil; 1-3% of cetearyl alcohol; 1-3% of shea butter; arlacel 1651-3%; 2-4% of polydimethylsiloxane; acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer 0.1-0.3%; 0.05 to 0.15 percent of tromethamine; 0.3 to 0.5 percent of p-hydroxyacetophenone; 0.3 to 0.5 percent of phenoxyethanol; 0.05 to 0.15 percent of tocopherol acetate; 0.01 to 0.10 percent of essence; 0.01-0.5% of collagen; 0.05-0.25% of biological polysaccharide; 0.5-2.0% of rhamnose soothing agent; 0.05-1.0% of ceramide; the balance being water.

10. Use of a soothing repair composition according to any one of claims 1 to 3, or a topical skin preparation according to any one of claims 5 to 9, in any one or more of:

(1) skin care;

(2) anti-inflammatory soothing of the skin;

(3) removing red skin and relieving itching;

(4) barrier repair of the skin.